Sigma-Aldrich Corporation (SIAL) announced that the Cerilliant brand, within its Applied Diagnostics and Testing division, has launched new solution-based Certified Reference Materials (CRMs) of seven Cannabis biomarkers.
The cannabinoid CRMs are appropriate for use in Cannabis testing applications by GC, GC/MS, HPLC, or LC-MS/MS, including potency testing, cannabinoid and impurity profiling, pharmaceutical research, or forensic analysis. They can also be used for the treatment of various ailments like arthritis, glaucoma and chronic pain to malnutrition, multiple sclerosis, epilepsy, and cancer.
The pharmacological and regulatory complexities involving Cannabis requires analytical testing of quality and potency to ensure safety of customers where its sale is legal for medicinal applications. For instance, the state of Colorado needs the Cannabis retailers to provide a cannabinoid potency profile for Cannabis-derived products. Canada on the other hand keeps production under control by strain that Cannabis growers must follow for cannabinoid profiling, cultivating, processing, quality control testing, and packaging.
Cerilliant's cannabinoid solution CRMs are certified to the highest industry standards including ISO Guide 34, ISO/IEC 17025, and ISO 13485 which include a comprehensive Certificate of Analysis (COA) containing uncertainty and traceability information. The information are as per ISO guidelines and for the satisfaction of laboratory regulatory requirements.
Sigma-Aldrich released its third-quarter 2014 results in Oct 2014. The company saw its profit slip in the quarter as higher charges offset a rise in its top line. Sigma-Aldrich reported a profit of $108 million or 90 cents per share in the quarter, roughly a 9% fall from $119 million or 98 cents per share reported a year ago.
Excluding charges associated with restructuring, and merger and acquisition activities, earnings were $1.06 per share in the reported quarter compared with $1.05 per share a year ago. Earnings matched the Zacks Consensus Estimate. The company recorded charges of $19 million (or 16 cents per share) in the reported quarter versus $8 million (or 7 cents per share) a year ago.
Sales for the quarter went up around 4% year over year to $690 million on gains across the board, but fell shy of the Zacks Consensus Estimate of $691 million.
Sigma-Aldrich currently carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the specialty chemicals space include Minerals Technologies Inc. (MTX), NL Industries Inc. (NL) and Taminco Corporation (TAM). All of these sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment